US20200016231A1 - Biofilm disrupting composition - Google Patents

Biofilm disrupting composition Download PDF

Info

Publication number
US20200016231A1
US20200016231A1 US16/470,887 US201716470887A US2020016231A1 US 20200016231 A1 US20200016231 A1 US 20200016231A1 US 201716470887 A US201716470887 A US 201716470887A US 2020016231 A1 US2020016231 A1 US 2020016231A1
Authority
US
United States
Prior art keywords
antibiotic
biofilm
composition
based antioxidant
biologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/470,887
Inventor
Theerthankar Das Ashish Kumar
Jim Manos
Gregory Stuart Whiteley
Trevor Owen Glasbey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Whiteley Corp Pty Ltd
Original Assignee
University of Sydney
Whiteley Corp Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905326A external-priority patent/AU2016905326A0/en
Application filed by University of Sydney, Whiteley Corp Pty Ltd filed Critical University of Sydney
Publication of US20200016231A1 publication Critical patent/US20200016231A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the invention relates to a biofilm disrupting composition for use in treating biofilm-mediated infections due to non- Pseudomonas micro-organisms in the Cystic Fibrosis patient.
  • a biofilm is any group of microorganisms in which cells stick to each other and often these cells adhere to a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS).
  • the biofilm EPS is typically comprised of a polymeric conglomeration generally composed of extracellular DNA (eDNA), proteins, and polysaccharides. Biofilms may form on living or non-living surfaces and can be prevalent in natural, industrial and hospital settings.
  • the sessile microbial cells growing in a biofilm are physiologically distinct from planktonic cells of the same organism, which, by contrast, are single-cells that may float or swim in a liquid medium.
  • Microbes form a biofilm in response to many factors, which may include cellular recognition of specific or non-specific attachment sites on a surface, nutritional cues, or in some cases, by exposure of planktonic cells to sub-inhibitory concentrations of antibiotics.
  • a cell switches to the biofilm mode of growth, it undergoes a phenotypic shift in behavior in which large suites of genes are differentially regulated.
  • microorganisms demonstrate significantly greater resistance to both biocides and antibiotics. This resistance feature of sessile microbes is a dual function of the enhanced genetic expression and also shielding by the surrounding polymeric materials of the biofilm.
  • Traditional antimicrobial therapies have been ineffective in the treatment of bacterial infections when the bacteria are located within a biofilm which is within, adherent to, or above tissue or located within a void such as the lungs or bladder, or in nasal passages or on the surface of a wound or burn. The additional risk of a multi-drug-resistant-organism increases the likelihood of significant morbidity or even death.
  • GSH Inhaled glutathione
  • GSH and DNase I can be combined for treating chronic Pseudomonas infections in individuals with cystic fibrosis (Klare et al., Canberra ASM meeting, July 2015). Further, GSH and DNase I have been found to be useful in the disruption of Pseudomonas biofilms in cystic fibrosis-like media and increasing susceptibility of the Pseudomonas aeruginosa to antibiotics (Klare et al., 2016 Antimicrobial Agents Chemotherapy 60 (8) 4539-4551), particularly when incorporated with an antibiotic such as Ciprofloxacin.
  • the effectiveness of the combination of Glutathione and DNase I can be ascribed to the nature of the biofilms formed by Pseudomonas spp.
  • the biofilm matrix consists predominantly of polysaccharides, proteins, and nucleic acids.
  • EPSs exopolysaccharides
  • Pseudomonas aeruginosa is also known to release exoproducts into the EPS.
  • the blue, redox-active phenazine derivative called pyocyanin also contributes to the viscosity of the EPS by intercalating directly with the EPS.
  • Pyocyanin has also been demonstrated to promote the release of eDNA from P. aeruginosa (see Das T, and Manefield M, “ Pyocyanin Promotes Extracellular DNA Release in Pseudomonas aeruginosa ”; Plos One (2012), 7, e46718).
  • Pyocyanin also contributes to the disease processes in Cystic Fibrosis. In vitro studies have shown that pyocyanin has multiple deleterious effects on mammalian cells, such as inhibition of cell respiration, ciliary function, epidermal cell growth and prostacyclin release, disruption of calcium homeostasis, and inactivation of catalase. Pyocyanin also induces apoptosis in neutrophils and modulates the glutathione redox cycle in lung epithelial and endothelial cells. It also inactivates al protease inhibitor and contributes to the imbalance of protease-antiprotease activity, which is readily detected in the airways of patients with CF lung disease.
  • the youngest age groups also had the highest proportions with positive cultures of the bacteria Escherichia coli; 12 percent, for those in the age (source: “CYSTIC FIBROSIS IN AUSTRALIA 2014”, 17th Annual Report from the Australian Cystic Fibrosis Data Registry, Cystic Fibrosis Australia (2016), North Ryde, NSW, Australia).
  • FIG. 1 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Pseudomonas aeruginosa both individually and in combination (two component combination), according to comparative Example 2.
  • FIG. 2 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Staphylococcus aureus (MRSA) both individually and in combination (two component combination), according to Example 3.
  • FIG. 3 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Staphylococcus aureus MSSA both individually and in combination (two component combination), according to Example 4.
  • FIG. 4 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Streptococcus agalactiae both individually and in combination (two component combination), according to Example 5.
  • FIG. 5 shows the effects of amikacin and glutathione on the biofilm viability of Acinetobacter baumaunii multi drug resistant (MRAB) both individually and in combination (two component combination), according to Example 6.
  • FIG. 6 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Klebsiella pneumoniae both individually and in combination (two component combination), according to Example 7.
  • FIG. 7 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Enterobacter species both individually and in combination (two component combination), according to Example 8.
  • FIG. 8 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Escherichia coli both individually and in combination (two component combination), according to Example 9.
  • FIG. 9 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Streptococcus pyogenes both individually and in combination (two component combination), according to Example 10.
  • FIG. 10 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Staphylococcus aureus (MRSA) both individually, and in both dual and triple combination (three component combination), according to Example 11.
  • FIG. 11 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Staphylococcus aureus (MSSA) both individually, and in both dual and triple combination (three component combination), according to Example 12.
  • FIG. 12 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Streptococcus agalactiae both individually, and in both dual and triple combination (three component combination), according to Example 13.
  • FIG. 13 shows the effects of amikacin, glutathione and DNase I on the biofilm viability of Acinetobacter baumannii (MRAB) both individually, and in both dual and triple combination (three component combination), according to Example 14.
  • a biofilm disrupting composition comprising:
  • a biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
  • a biofilm disrupting composition comprising:
  • a biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
  • a process of preparing a biofilm disrupting composition according to the first and second embodiments, which process comprises combining at least one biologically acceptable thiol based antioxidant and at least one antibiotic, to form said composition.
  • a process of preparing a biofilm disrupting composition comprises combining at least one biologically acceptable thiol based antioxidant, at least one antibiotic and at least one enzyme, to form said composition.
  • composition comprising:
  • a method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient comprises administering to said patient a composition according to any one of the first, second, third or fourth embodiments in an amount which effectively disrupts said biofilm.
  • thiol based antioxidant is a substance that is tolerated without ill effect by a living body, and contains a sulfhydryl moiety, and where said substance can inhibit the oxidation of other molecules.
  • composition of the invention act synergistically providing superior biofilm disruption.
  • composition of the invention comprises at least one biologically acceptable thiol based antioxidant.
  • This is a biologically and pharmaceutically acceptable compound capable of reducing disulfide bonds formed within cytoplasmic proteins to cysteines by serving as an electron donor.
  • suitable biologically acceptable thiol based antioxidants include mercaptoethanol, N-acetyl cysteine (NAC), glutathione (GSH), thiamphenicol glycinate acetylcysteinate (TGA), sodium mercaptoethane sulfonate, dithiothreitol (DTT), dithiobutylamine and other similar compounds.
  • suitable biologically acceptable thiol based antioxidants are compounds such as lipoic acid or erdosteine, which are capable of generating free thiol groups in vivo following first pass metabolism.
  • the biologically acceptable thiol based antioxidant is glutathione (GSH).
  • the composition of the invention comprises at least one antibiotic capable of killing either or both Gram Positive or Gram Negative organisms.
  • the antibiotic may be selected from the non-limiting group of antibiotic classes consisting of Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems.
  • Specific examples of useful antibiotics include ciprofloxacin, amoxicillin/clavulanate, cefixime, cefalosporin cefaclor, clarithromycin, levofloxacin, moxifloxacin, gentamycin, vancomycin and telithromycin.
  • composition of the invention comprises one or more enzymes capable of degrading one or more of the biopolymers that make up the biofilm.
  • the enzymes may be selected from the (non-limiting) group consisting of protease, amylase, cellulase, and DNase.
  • the composition of the invention will contain two or more of these enzyme types.
  • at least one of the enzymes is DNase.
  • the biofilm disrupting composition may optionally contain other ingredients such as tonicity modifiers, pH buffers, colourants, preservatives and perfumes.
  • composition of the invention may also contain tonicity modifying ingredients. These may comprise inorganic salts, for example sodium bromide, potassium bromide, sodium chloride, potassium chloride, sodium acetate, potassium acetate, sodium citrate, potassium citrate, sodium phosphate, potassium phosphate, or may comprise organic tonicity modifiers such as propylene glycol, glycerol, mannitol, arabitol, glucose, fructose etc.
  • the composition of the invention may be isotonic (i.e. 250-350 mOsmal/Kg) or hypotonic (i.e. ⁇ 250 mOsmal/Kg).
  • the composition of the invention may also comprise colouring agents.
  • the colouring agents may be added to provide a function to the composition, such as the staining of components found within the bacterial biofilm, or may just be added to provide an aesthetically pleasing solution.
  • the resultant staining may provide a visual cue as to the presence of the biofilm, thus also provide a means of monitoring its removal.
  • Suitable colouring agents capable of staining biofilm components will include Coomassie Brilliant Blue, Crystal Violet, erythrosine and tartrazine.
  • the biofilm disrupting composition may be in solid form, or the composition may be a solution.
  • the mixture may comprise one or more processing aids such as mannitol, starch, glucose, sucrose etc. in order to allow the composition to be processed into micronized particles, preferably with a mean particle size of less than 500 microns.
  • the micronized composition will have a mean particle size of less than 100 microns, and in a particularly preferred embodiment, the micronized composition will have a mean particle size of less than 40 microns.
  • the micronized composition of this particularly preferred embodiment is suitable for inhalation and useful for the disruption and removal of bacterial biofilms found in the lungs in conditions such as cystic fibrosis, bronchitis, chronic obstructive pulmonary disease (COPD), and other airway infections in which biofilms due to non-Pseudomonad micro-organisms are implicated, such as recurrent rhinosinusitis or pharyngotonsillitis.
  • COPD chronic obstructive pulmonary disease
  • the mixture may contain one or more processing aids such as wetting agents, defoaming agents, antioxidants, viscosity modifiers etc.
  • FIGS. 2-13 Combining GSH with low concentration of antibiotics enhances biofilms disruptions and killing.
  • DNase I by itself has no effect on Staphylococcus aureus and Streptococcus agalactiae biofilms disruption (see FIGS. 10 and 11 ), but Dnase I by itself has some effect on MRAB biofilms disruption (see FIG. 13 ).
  • 3 component combination therapy (GSH+DNase I+Ciprofloxacin) used for Staphylococcus aureus and Streptococcus agalactiae has similar effect as GSH+ciprofloxacin (2 component combination therapy (2CT).
  • 3CT use for MRAB (GSH+DNase I+Amikacin) showed significantly better disruption/killing.
  • Ciprofloxacin All strains sensitive to Ciprofloxacin (except for Acinetobacter baumannii ). Many strains are resistant to different antibiotics including: penicillin, gentamicin, amoxycillin/Clavulanate, Cefazolin, am ikacin.
  • TAB Tryptone Soya Broth
  • treated biofilms supernatant were replaced with 200 ⁇ L of 1 ⁇ PBS, followed by addition of 15 ⁇ L of a 0.05% w/v solution of resazurin (Sigma-Aldrich), and incubated further at 37° C., 150 r.p.m.
  • the fluorescent intensity of the biofilm was determined at Ex544 nm and Em590 nm (Tecan infinite M1000 pro microplate reader). Results are plotted as percentage (%) of bacterial vaiability calculated based on fluorescent intensity. Control or untreated bacterial biofilm fluorescent intensity always considered as 100% bacterial viability and % viability under rest of treatment conditions were calculated with reference to control.
  • Resazurin assay works by recording fluorescence intensity and depends upon two factors (total number of bacteria and total number of viable bacteria in a given biofilm sample).
  • Example 2 is a comparative, prior art, example demonstrating the use of the combination of glutathione with an antibiotic, ciprofloxacin. As previously discussed, it is widely believed that the role of the glutathione is to deactivate the pyocyanin released by Pseudomonas aeruginosa . It is noted that the treatments shown in column 1 of Table 2 were tested against three clinical isolates of Pseudomonas aeruginosa . The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 1 ).
  • Example 3 Methicillin Resistant Staphylococcus aureus (MRSA: Clinical Isolates)
  • Example 5 Staphylococcus agalactiae (Ex Cow Mastitis)
  • Example 11 Methicillin Resistant Staphylococcus aureus (Clinical Isolates)
  • Example 13 Staphylococcus agalactiae (Ex Cow Mastitis)
  • Example 14 Multi Drug Resistant Acinetobacter baumannii

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A biofilm disrupting composition for use in treating biofilm-mediated infections due to non-Pseudomonas micro-organisms in the Cystic Fibrosis patient. One embodiment of the composition of the invention comprises at least one biologically acceptable thiol based antioxidant and at least one antibiotic. Another embodiment of the composition of the invention comprises at least one biologically acceptable thiol based antioxidant, at least one enzyme and at least one antibiotic. The invention is also directed to the process of preparing the composition of the invention, the use of the composition for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms, and a method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient, comprising administering to the patient the composition of the invention.

Description

    FIELD OF THE INVENTION
  • The invention relates to a biofilm disrupting composition for use in treating biofilm-mediated infections due to non-Pseudomonas micro-organisms in the Cystic Fibrosis patient.
    • BACKGROUND OF INVENTION
  • A biofilm is any group of microorganisms in which cells stick to each other and often these cells adhere to a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). The biofilm EPS is typically comprised of a polymeric conglomeration generally composed of extracellular DNA (eDNA), proteins, and polysaccharides. Biofilms may form on living or non-living surfaces and can be prevalent in natural, industrial and hospital settings. The sessile microbial cells growing in a biofilm are physiologically distinct from planktonic cells of the same organism, which, by contrast, are single-cells that may float or swim in a liquid medium.
  • Microbes form a biofilm in response to many factors, which may include cellular recognition of specific or non-specific attachment sites on a surface, nutritional cues, or in some cases, by exposure of planktonic cells to sub-inhibitory concentrations of antibiotics. When a cell switches to the biofilm mode of growth, it undergoes a phenotypic shift in behavior in which large suites of genes are differentially regulated.
  • Within a biofilm structure, microorganisms demonstrate significantly greater resistance to both biocides and antibiotics. This resistance feature of sessile microbes is a dual function of the enhanced genetic expression and also shielding by the surrounding polymeric materials of the biofilm. Traditional antimicrobial therapies have been ineffective in the treatment of bacterial infections when the bacteria are located within a biofilm which is within, adherent to, or above tissue or located within a void such as the lungs or bladder, or in nasal passages or on the surface of a wound or burn. The additional risk of a multi-drug-resistant-organism increases the likelihood of significant morbidity or even death.
  • Inhaled glutathione (GSH) therapy has been used to reduce oxidative stress in cystic fibrosis patients and inhibit proliferation of Pseudomonas infections in cystic fibrosis patients, including increasing susceptibility of the Pseudomonas to antibiotics (Zhang Y and Duan K, “Glutathione exhibits antibacterial activity and increases tetracycline efficacy against Pseudomonas aeruginosa”; Sci. China Ser. C, (2009) 52:501-505.
  • It has also been found that GSH and DNase I can be combined for treating chronic Pseudomonas infections in individuals with cystic fibrosis (Klare et al., Canberra ASM meeting, July 2015). Further, GSH and DNase I have been found to be useful in the disruption of Pseudomonas biofilms in cystic fibrosis-like media and increasing susceptibility of the Pseudomonas aeruginosa to antibiotics (Klare et al., 2016 Antimicrobial Agents Chemotherapy 60 (8) 4539-4551), particularly when incorporated with an antibiotic such as Ciprofloxacin.
  • The effectiveness of the combination of Glutathione and DNase I can be ascribed to the nature of the biofilms formed by Pseudomonas spp. The biofilm matrix consists predominantly of polysaccharides, proteins, and nucleic acids. Despite macromolecule heterogeneity, most research has focused on the role of bacterially produced exopolysaccharides (EPSs) in biofilm establishment and maturation.
  • The integral role of extracellular DNA in biofilm formation was first identified in P. aeruginosa by Whitchurch et al (Whitchurch C B, Tolker-Nielsen T, Ragas P C, Mattick J S. “Extracellular DNA required for bacterial biofilm formation”. Science (2002) 295:1487. doi:10.1126/science.295.5559.1487), but eDNA has since been shown to be a ubiquitous biofilm matrix polymer across most Gram-positive and Gram-negative bacterial species. In fact, within P. aeruginosa biofilms, eDNA is the most abundant matrix polymer (see Matsukawa M, Greenberg E P. “Putative exopolysaccharide synthesis genes influence Pseudomonas aeruginosa biofilm development”. J Bacteriol (2004) 186:4449-4456. doi:10.1128/JB.186.14.4449-4456.2004. and Okshevsky M, Meyer R L. “The role of extracellular DNA in the establishment, maintenance and perpetuation of bacterial biofilms”. Crit Rev Microbiol (2013) 41:341-352). The eDNA also serves as a structural component of the EPS and contributes to its viscosity.
  • Pseudomonas aeruginosa is also known to release exoproducts into the EPS. One of these exoproducts, the blue, redox-active phenazine derivative called pyocyanin also contributes to the viscosity of the EPS by intercalating directly with the EPS. Pyocyanin has also been demonstrated to promote the release of eDNA from P. aeruginosa (see Das T, and Manefield M, “Pyocyanin Promotes Extracellular DNA Release in Pseudomonas aeruginosa”; Plos One (2012), 7, e46718).
  • Pyocyanin also contributes to the disease processes in Cystic Fibrosis. In vitro studies have shown that pyocyanin has multiple deleterious effects on mammalian cells, such as inhibition of cell respiration, ciliary function, epidermal cell growth and prostacyclin release, disruption of calcium homeostasis, and inactivation of catalase. Pyocyanin also induces apoptosis in neutrophils and modulates the glutathione redox cycle in lung epithelial and endothelial cells. It also inactivates al protease inhibitor and contributes to the imbalance of protease-antiprotease activity, which is readily detected in the airways of patients with CF lung disease. More recently, it was shown that pyocyanin inactivates the vacuolar ATPase of lung epithelial cells (See Lau G W et al., “Pseudomonas aeruginosa Pyocyanin Is Critical for Lung Infection in Mice”. Infect. Immun. (2004) 72 4275-4278 and references therein)
  • The most commonly identified organisms in respiratory specimens taken from Cystic Fibrosis patients are various species and forms of Pseudomonas. It can be seen that 48.5 percent of patients tested produced positive Pseudomonas aeruginosa cultures, with the mucoid form showing in 32.0 percent. Its prevalence is greater in adult patients, with 60.9 percent of tested adult CF patients producing samples indicating the mucoid form of Pseudomonas aeruginosa, three times the corresponding proportion for adolescents and much higher than that for children.
  • While prevalence of Pseudomonas organisms is lower in children than in adults, although increasing with rising age, young children are more likely than adult patients to produce cultures showing presence of Staphylococcus aureus (see table 1). Half of all child patients and adolescent patients aged 6 to 17 years had this bacterial infection. Haemophilus influenza is also evident in relatively high proportions of child patients, highest in children aged from 2 to 5 years, where this organism was cultured for almost one third of children. The youngest age groups also had the highest proportions with positive cultures of the bacteria Escherichia coli; 12 percent, for those in the age (source: “CYSTIC FIBROSIS IN AUSTRALIA 2014”, 17th Annual Report from the Australian Cystic Fibrosis Data Registry, Cystic Fibrosis Australia (2016), North Ryde, NSW, Australia).
  • TABLE 1
    Percentages of other respiratory cultures by age group (other than Pseudomonas)
    Age Range
    0-1 2-5 6-11 12-17 18-29 30+ Total
    Bacteria:
    Staphylococcus aureus 39.0 42.6 47.6 50.3 38.6 30.7 41.8
    Haemophilus influenzae 28.0 32.3 23.7 11.3 7.1 2.3 14.5
    Burkholderia cepacia 0.0 0.0 1.6 2.1 4.2 2.8 2.3
    Stenotrophomonas maltophilia 5.0 3.8 10.2 14.4 7.7 6.5 8.7
    Escherichia coli 12.0 8.9 6.5 3.1 1.0 0.6 4.0
    MRSA (Methicillin Resistant 2.0 1.7 1.9 3.4 2.5 3.4 2.6
    Staphylococcus aureus)
    Alcaligenes xylosoxidans 0.0 0.4 3.0 2.6 5.0 5.6 3.5
    Serratia marcescens 2.0 1.7 0.9 1.3 0.8 0.0 0.9
    Klebsiella (any species) 9.0 3.0 0.7 1.6 0.6 1.1 1.6
    Non-tuberculous mycobacterium 0.0 0.0 0.0 3.1 4.6 4.2 2.5
    Fungi:
    Candida 18.0 22.1 24.6 34.8 27.8 29.3 27.6
    Aspergillus (any species) 8.0 10.2 22.0 33.5 29.2 22.3 24.0
    Scediosporium (any species) 0.0 0.4 2.6 6.3 5.0 3.4 3.7
    Other organisms not listed 28.0 33.2 30.4 29.1 20.8 19.7 26.0
    above
    Normal flora only 63.0 79.1 82.8 77.5 38.0 28.5 59.4
    No growth/sterile culture 10.0 8.1 7.0 4.5 4.2 3.4 5.4
    Patients tested 100 235 431 382 518 355 2021
  • It is evident therefore that whilst the bulk of respiratory infections in Cystic Fibrosis sufferers are due to Pseudomonas, a significant number of patients show infections due to other biofilm generating organisms such as Staphylococcus aureus and Haemophilus influenzae, neither of which release pyocyanin.
    • DESCRIPTION OF FIGURES
  • FIG. 1 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Pseudomonas aeruginosa both individually and in combination (two component combination), according to comparative Example 2.
  • FIG. 2 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Staphylococcus aureus (MRSA) both individually and in combination (two component combination), according to Example 3.
  • FIG. 3 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Staphylococcus aureus MSSA both individually and in combination (two component combination), according to Example 4.
  • FIG. 4 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Streptococcus agalactiae both individually and in combination (two component combination), according to Example 5.
  • FIG. 5 shows the effects of amikacin and glutathione on the biofilm viability of Acinetobacter baumaunii multi drug resistant (MRAB) both individually and in combination (two component combination), according to Example 6.
  • FIG. 6 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Klebsiella pneumoniae both individually and in combination (two component combination), according to Example 7.
  • FIG. 7 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Enterobacter species both individually and in combination (two component combination), according to Example 8.
  • FIG. 8 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Escherichia coli both individually and in combination (two component combination), according to Example 9.
  • FIG. 9 shows the effects of ciprofloxacin and glutathione on the biofilm viability of Streptococcus pyogenes both individually and in combination (two component combination), according to Example 10.
  • FIG. 10 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Staphylococcus aureus (MRSA) both individually, and in both dual and triple combination (three component combination), according to Example 11.
  • FIG. 11 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Staphylococcus aureus (MSSA) both individually, and in both dual and triple combination (three component combination), according to Example 12.
  • FIG. 12 shows the effects of ciprofloxacin, glutathione and DNase I on the biofilm viability of Streptococcus agalactiae both individually, and in both dual and triple combination (three component combination), according to Example 13.
  • FIG. 13 shows the effects of amikacin, glutathione and DNase I on the biofilm viability of Acinetobacter baumannii (MRAB) both individually, and in both dual and triple combination (three component combination), according to Example 14.
    •  SUMMARY OF THE INVENTION
  • Whilst it may be expected that the combination of DNase I and an antibiotic will show activity against biofilms, it has been surprisingly found that a biologically acceptable thiol based antioxidant can also serve to disrupt biofilms formed from organisms other than the pyocyanin-producing Pseudomonas.
  • It has also been unexpectedly found that the combination of a biologically acceptable thiol based antioxidant, an enzyme and an antibiotic also demonstrate a synergistic effect against biofilms formed by organisms other than Pseudomonas (ie non-Pseudomonad organisms).
  • According to a first embodiment of the invention, there is provided a biofilm disrupting composition comprising:
      • (a) at least one biologically acceptable thiol based antioxidant, and
      • (b) at least one antibiotic,
      • wherein said composition is capable of disrupting biofilms formed by non-Pseudomonad micro-organisms.
  • According to a second embodiment of the invention, there is provided a biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
      • (a) at least one biologically acceptable thiol based antioxidant, and
      • (b) at least one antibiotic.
  • According to a third embodiment of the invention, there is provided a biofilm disrupting composition comprising:
      • (a) at least one biologically acceptable thiol based antioxidant,
      • (b) at least one enzyme and
      • (c) at least one antibiotic,
        wherein said composition is capable of disrupting biofilms formed by non-Pseudomonad micro-organisms.
  • According to a fourth embodiment of the invention, there is provided a biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
      • (a) at least one biologically acceptable thiol based antioxidant,
      • (b) at least one enzyme and
      • (d) at least one antibiotic.
  • According to a fifth embodiment of the invention, there is provided a process of preparing a biofilm disrupting composition according to the first and second embodiments, which process comprises combining at least one biologically acceptable thiol based antioxidant and at least one antibiotic, to form said composition.
  • According to a sixth embodiment of the invention, there is provided a process of preparing a biofilm disrupting composition according to the third and fourth embodiments, which process comprises combining at least one biologically acceptable thiol based antioxidant, at least one antibiotic and at least one enzyme, to form said composition.
  • According to a seventh embodiment of the invention, there is provided the use of a composition comprising:
      • (a) at least one biologically acceptable thiol based antioxidant, and
      • (b) at least one antibiotic,
        for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms.
  • According to an eighth embodiment of the invention, there is provided the use of a composition comprising:
      • (a) at least one biologically acceptable thiol based antioxidant,
      • (b) at least one enzyme and
      • (c) at least one antibiotic,
        for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms.
  • According to a ninth embodiment of the invention, there is provided a method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient, which method comprises administering to said patient a composition according to any one of the first, second, third or fourth embodiments in an amount which effectively disrupts said biofilm.
  • By biologically acceptable thiol based antioxidant it is understood that this is a substance that is tolerated without ill effect by a living body, and contains a sulfhydryl moiety, and where said substance can inhibit the oxidation of other molecules.
  • Throughout the description and claims of the specification, the word “comprise” and variations of the word, such as “comprising” and “comprises”, is not intended to exclude other additives, components, integers or steps.
  • The ingredients of the composition of the invention act synergistically providing superior biofilm disruption.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Biologically Acceptable Thiol Based Antioxidant
  • The composition of the invention comprises at least one biologically acceptable thiol based antioxidant. This is a biologically and pharmaceutically acceptable compound capable of reducing disulfide bonds formed within cytoplasmic proteins to cysteines by serving as an electron donor.
  • Examples of suitable biologically acceptable thiol based antioxidants include mercaptoethanol, N-acetyl cysteine (NAC), glutathione (GSH), thiamphenicol glycinate acetylcysteinate (TGA), sodium mercaptoethane sulfonate, dithiothreitol (DTT), dithiobutylamine and other similar compounds. Other examples of suitable biologically acceptable thiol based antioxidants are compounds such as lipoic acid or erdosteine, which are capable of generating free thiol groups in vivo following first pass metabolism. In a preferred embodiment the biologically acceptable thiol based antioxidant is glutathione (GSH).
  • Antibiotic
  • The composition of the invention comprises at least one antibiotic capable of killing either or both Gram Positive or Gram Negative organisms. The antibiotic may be selected from the non-limiting group of antibiotic classes consisting of Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems. Specific examples of useful antibiotics include ciprofloxacin, amoxicillin/clavulanate, cefixime, cefalosporin cefaclor, clarithromycin, levofloxacin, moxifloxacin, gentamycin, vancomycin and telithromycin.
  • Enzymes
  • The composition of the invention comprises one or more enzymes capable of degrading one or more of the biopolymers that make up the biofilm.
  • The enzymes may be selected from the (non-limiting) group consisting of protease, amylase, cellulase, and DNase. In a preferred embodiment, the composition of the invention will contain two or more of these enzyme types. Preferably at least one of the enzymes is DNase.
  • Optional Ancillary Agents
  • The biofilm disrupting composition may optionally contain other ingredients such as tonicity modifiers, pH buffers, colourants, preservatives and perfumes.
  • Tonicity Modifying Agent
  • The composition of the invention may also contain tonicity modifying ingredients. These may comprise inorganic salts, for example sodium bromide, potassium bromide, sodium chloride, potassium chloride, sodium acetate, potassium acetate, sodium citrate, potassium citrate, sodium phosphate, potassium phosphate, or may comprise organic tonicity modifiers such as propylene glycol, glycerol, mannitol, arabitol, glucose, fructose etc. The composition of the invention may be isotonic (i.e. 250-350 mOsmal/Kg) or hypotonic (i.e. <250 mOsmal/Kg).
  • Colouring Agent
  • The composition of the invention may also comprise colouring agents. The colouring agents may be added to provide a function to the composition, such as the staining of components found within the bacterial biofilm, or may just be added to provide an aesthetically pleasing solution. When the colouring agent is added to stain components of the biofilm, the resultant staining may provide a visual cue as to the presence of the biofilm, thus also provide a means of monitoring its removal. Suitable colouring agents capable of staining biofilm components (for example protein, polysaccharide or bacterial cell walls) will include Coomassie Brilliant Blue, Crystal Violet, erythrosine and tartrazine.
  • Processing Aids
  • The biofilm disrupting composition may be in solid form, or the composition may be a solution. In the case of a solid mixture of ingredients, the mixture may comprise one or more processing aids such as mannitol, starch, glucose, sucrose etc. in order to allow the composition to be processed into micronized particles, preferably with a mean particle size of less than 500 microns. In a more preferred embodiment, the micronized composition will have a mean particle size of less than 100 microns, and in a particularly preferred embodiment, the micronized composition will have a mean particle size of less than 40 microns. The micronized composition of this particularly preferred embodiment is suitable for inhalation and useful for the disruption and removal of bacterial biofilms found in the lungs in conditions such as cystic fibrosis, bronchitis, chronic obstructive pulmonary disease (COPD), and other airway infections in which biofilms due to non-Pseudomonad micro-organisms are implicated, such as recurrent rhinosinusitis or pharyngotonsillitis.
  • In the case of a liquid composition, the mixture may contain one or more processing aids such as wetting agents, defoaming agents, antioxidants, viscosity modifiers etc.
  • Observed Results
  • Glutathione (GSH) especially at 30 milli Molar (3 times higher than biological intracellular concentration which is 2-10 millimolar) shows significantly higher effect than antibiotics in killing/disrupting biofilms, even against non-Pseudomonad organisms (see FIGS. 1-13).
  • Combining GSH with low concentration of antibiotics (FIGS. 2-13) enhances biofilms disruptions and killing.
  • DNase I by itself has no effect on Staphylococcus aureus and Streptococcus agalactiae biofilms disruption (see FIGS. 10 and 11), but Dnase I by itself has some effect on MRAB biofilms disruption (see FIG. 13).
  • Consequently 3 component combination therapy (3CT) (GSH+DNase I+Ciprofloxacin) used for Staphylococcus aureus and Streptococcus agalactiae has similar effect as GSH+ciprofloxacin (2 component combination therapy (2CT). 3CT use for MRAB (GSH+DNase I+Amikacin) showed significantly better disruption/killing.
    • EXAMPLES
  • In the following examples, all clinical isolates were taken from various hospitals in the Sydney, NSW area. Streptococcus agalactiae from Cow mastitis, isolated on a NSW farm.
  • All strains sensitive to Ciprofloxacin (except for Acinetobacter baumannii). Many strains are resistant to different antibiotics including: penicillin, gentamicin, amoxycillin/Clavulanate, Cefazolin, am ikacin.
    • Example 1: Experimental Protocol
  • Bacterial isolates were grown in Tryptone Soya Broth (TSB) medium for 24 hours at 37° C., in a shaking incubator set at 150 rpm. After this time the organisms were harvested by centrifugation (5000×g, 5 min at 10° C.). After centrifugation, the supernatant liquid was removed and the bacterial pellet was suspended in 1×Phosphate Buffered Saline (PBS). To initiate biofilm growth, the bacterial suspension from PBS was immediately re-suspended in TSB and 250 μL of bacterial cell suspension (OD600=0.5±0.05) were added into the wells of 96-well plates (Corning Corp. USA) and incubated at 37° C. for 48 h at 150 r.p.m.
  • After 48 h, biofilm were washed once with 1×PBS followed by treatment (for 24 h, 37° C., 150 rpm under different conditions: either with Ciprofloxacin or Amikacin, DNase I (40 U solution, Sigma Aldrich) or GSH ( different concentration 10, 15 and 30 milliMolar solutions in PBS) individually or combination: DNase I+ciprofloxacin or Amikacin, GSH+DNase I, GSH+ciprofloxacin or Amikacin and GSH+DNase I+Ciprofloxacin or Amikacin. The composition of the treatments used are given in the subsequent examples
  • After 24 h, treated biofilms supernatant were replaced with 200 μL of 1×PBS, followed by addition of 15 μL of a 0.05% w/v solution of resazurin (Sigma-Aldrich), and incubated further at 37° C., 150 r.p.m.
  • After a further 24 h, the fluorescent intensity of the biofilm was determined at Ex544 nm and Em590 nm (Tecan infinite M1000 pro microplate reader). Results are plotted as percentage (%) of bacterial vaiability calculated based on fluorescent intensity. Control or untreated bacterial biofilm fluorescent intensity always considered as 100% bacterial viability and % viability under rest of treatment conditions were calculated with reference to control.
  • It should be noted that the Resazurin assay works by recording fluorescence intensity and depends upon two factors (total number of bacteria and total number of viable bacteria in a given biofilm sample).
    • Example 2: Pseudomonas aeruginosa (Clinical Isolates)
  • Example 2 is a comparative, prior art, example demonstrating the use of the combination of glutathione with an antibiotic, ciprofloxacin. As previously discussed, it is widely believed that the role of the glutathione is to deactivate the pyocyanin released by Pseudomonas aeruginosa. It is noted that the treatments shown in column 1 of Table 2 were tested against three clinical isolates of Pseudomonas aeruginosa. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 1).
  • TABLE 2
    Pseudomonas aeruginosa isolate and source
    PA0053
    365707 Left 364077 Scalp
    Treatment DFU ankle wound wound
    Control 100.0 100.0 100.0
    CIP 0.5 μg/ml 12.2 22.0 9.7
    CIP 1 μg/ml 8.7 21.3 6.8
    CIP2 μg/ml 5.8 25.9 6.5
    GSH 10 mM 89.8 103.5 95.6
    GSH 15 mM 74.5 100.9 93.0
    GSH 30 mM 7.3 11.2 30.3
    2 part CT 3.2 2.3 5.2
    GSH 30 mM
    CIP 0.5 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
  • The following examples illustrate the efficacy of the combination of a biologically acceptable thiol based antioxidant, with an antibiotic against biofilms formed by organisms other than Pseudomonas (i.e. non-Pseudomonad organisms).
    • Example 3: Methicillin Resistant Staphylococcus aureus (MRSA: Clinical Isolates)
  • The treatments shown in column 1 of Table 3 were tested against three strains of methicillin-resistant Staphylococcus aureus. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 2).
  • TABLE 3
    MRSA 27060 MRSA 30616 MRSA - 0799
    Treatment Left leg Chin vesicle DFU
    Control 100.00 100.00 100.00
    CIP 10 μg/ml 42.93 40.01 61.08
    CIP 20 μg/ml 25.74 31.38 54.21
    CIP30 μg/ml 19.53 24.56 51.60
    GSH 10 mM 88.83 73.12 86.73
    GSH 15 mM 65.24 58.82 75.03
    GSH 30 mM 1.02 4.54 33.12
    2 part CT −0.30 0.61 21.83
    GSH 30 mM
    CIP
    10 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 4: Methicillin Sensitive Staphylococcus aureus (MSSA: Clinical Isolate)
  • The treatments shown in column 1 of Table 4 were tested against three strains of methicillin-sensitive Staphylococcus aureus. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 3).
  • TABLE 4
    MSSA - 34397 MSSA - 34654 MSSA - 0800
    Treatment Left elbow Right toe DFU
    Control 100.00 100.00 100.00
    CIP 10 μg/ml 49.93 37.08 41.69
    CIP 20 μg/ml 36.78 32.05 32.03
    CIP 30 μg/ml 29.81 32.44 21.58
    GSH 10 mM 88.67 86.11 82.44
    GSH 15 mM 61.34 70.52 61.70
    GSH 30 mM 1.06 15.33 20.09
    2 part CT 0.77 5.85 9.68
    GSH 30 mM
    CIP10 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 5: Staphylococcus agalactiae (Ex Cow Mastitis)
  • The treatments shown in column 1 of Table 5 were tested against four strains of Staphylococcus agalactiae, (veterinary strains ex Cow mastitis). The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 4).
  • TABLE 5
    S. S. S. S. S.
    agalactiae agalactiae agalactiae agalactiae agalactiae
    Treatment # 30 # 44 # 70 # 88 # 106
    Control 100.00 100.00 100.00 100.00 100.00
    CIP 4 μg/ml 74.20 63.40 74.10 71.60 72.50
    CIP 8 μg/ml 66.38 66.52 65.26 69.79 70.13
    CIP 12 69.29 63.28 58.93 63.77 65.90
    μg/ml
    GSH
    10 mM 103.78 86.99 89.17 87.95 102.63
    GSH 15 mM 80.69 73.92 79.41 81.62 83.17
    GSH 30 mM 35.30 29.16 38.30 25.00 29.20
    2 part CT (1) 22.30 25.90 24.80 17.80 25.30
    GSH 30 mM
    CIP 4 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 6: Multi Drug Resistant Acinetobacter baumannii
  • The treatments shown in column 1 of Table 6 were tested against six clinical isolates of Multidrug resistant Acinetobacter Baumannii, (MRAB). The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 5). As these MRAB strains were resistant to ciprofloxacin, Amikacin was used instead.
  • TABLE 6
    MRAB 1 MRAB 2 MRAB 3 MRAB 4 MRAB 5 MRAB 12
    Strain ID 014754 014801 015069 015095 015103 016419
    Source Urine Catheter Skin Hospital Hospital Catheter
    Environ Environ
    Control 100.00 100.00 100.00 100.00 100.00 100.00
    AMI 4 μg/ml 35.91 35.99 66.60 66.36 65.23 49.66
    AMI12 μg/ml 24.47 14.11 48.60 42.91 26.85 22.70
    AMI20 μg/ml 14.67 8.36 41.70 33.92 24.60 19.80
    GSH 10 mM 73.61 70.84 84.56 68.00 65.08 80.83
    GSH 15 mM 55.58 41.23 63.18 57.70 51.49 49.05
    GSH 30 mM 20.35 2.45 37.70 13.77 16.71 18.41
    2 part CT (2) 6.90 1.53 4.69 6.85 10.96 4.30
    GSH 30 mM
    AMI 4 μg/ml
    Control = no treatment
    AMI = Amikacin
    GHS = glutathione
    • Example 7: Klebsiella pneumoniae (Clinical Isolates)
  • The treatments shown in column 1 of table 7 were tested against three clinical isolates of Klebsiella pneumoniae. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 6).
  • TABLE 7
    Klebsiella pneumoniae isolate and source
    374450 Catheter 377951 Left 385261 Neck
    Treatment urine hip wound wound
    Control 100.00 100.00 100.00
    CIP 10 μg/ml 37.55 54.58 29.48
    CIP 20 μg/ml 22.13 40.39 21.00
    CIP30 μg/ml 21.29 25.39 21.97
    GSH 10 mM 85.95 81.60 78.75
    GSH 15 mM 72.81 70.81 62.46
    GSH 30 mM 16.76 9.13 14.12
    2 part CT 10.32 1.80 4.15
    GSH 30 mM
    CIP
    10 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 8 Enterobacter Species (Clinical Isolates)
  • The treatments shown in column 1 of Table 8 were tested against three clinical isolates of Enterobacter species. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 7).
  • TABLE 8
    Enterobacter species and source
    E. cloacae E aerogenes
    E. cloacae 359315 Left 359475
    Treatment 357768 Ear foot wound Sternum
    Control 100.0 100.0 100.0
    CIP 0.5 μg/ml 39.2 64.0 14.6
    CIP 1 μg/ml 23.4 53.8 6.3
    CIP2 μg/ml 25.0 64.1 5.9
    GSH 10 mM 62.8 84.7 79.0
    GSH 15 mM 38.9 74.0 55.1
    GSH 30 mM 0.0 19.5 14.6
    2 part CT 0.0 8.5 2.3
    GSH 30 mM
    CIP 0.5 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 9 Escherichia coli (Clinical Isolates)
  • The treatments shown in column 1 of Table 9 were tested against three clinical isolates of Enterobacter species. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 8).
  • TABLE 9
    Escherichia coli and source
    362805 365714 366290 Drain
    Exit Wound fluid
    Control 100.0 100.0 100.0
    CIP 0.5 μg/ml 57.9 40.7 29.9
    CIP 1 μg/ml 48.1 36.4 29.4
    CIP2 μg/ml 48.7 31.3 30.8
    GSH 10 mM 75.7 107.5 69.8
    GSH 15 mM 71.8 93.4 68.7
    GSH 30 mM 0.7 12.3 3.9
    2 part CT 1.1 6.0 0.7
    GSH 30 mM
    CIP 0.5 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 10: Streptococcus pyogenes (Clinical Isolates)
  • The treatments shown in column 1 of Table 10 were tested against three clinical isolates of Enterobacter species. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 9).
  • TABLE 10
    Streptococcus pyogenes and source
    361194 Left 386596 Head 371982 Skin
    leg boil Wound Wound
    Control 100.0 100.0 100.0
    CIP 4 μg/ml 18.3 49.6 54.3
    CIP 8 μg/ml 10.1 46.8 56.5
    CIP 12 μg/ml 6.4 39.3 56.1
    GSH 10 mM 55.6 67.7 99.8
    GSH 15 mM 35.8 42.7 90.2
    GSH 30 mM 4.3 22.3 15.4
    2 part CT 0.1 11.8 4.8
    GSH 30 mM
    CIP 4 ug/ml
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
  • The following examples illustrate the efficacy of the triple combination of a biologically acceptable thiol based antioxidant, an antibiotic, along with an enzyme against biofilms formed by organisms other than Pseudomonas (ie non-Pseudomonad organisms). These represent the three part combination therapy (3 part CT).
    • Example 11: Methicillin Resistant Staphylococcus aureus (Clinical Isolates)
  • The treatments shown in column 1 of Table 11 were tested against three strains of methicillin-resistant Staphylococcus aureus. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 10).
  • TABLE 11
    MRSA 27060 MRSA 30616 MRSA - 0799
    Treatment Left leg Chin vesicle DFU
    Control 100.00 100.00 100.00
    CIP 10 μg/ml 42.93 40.01 61.08
    CIP 20 μg/ml 25.74 31.38 54.21
    CIP30 μg/ml 19.53 24.56 51.60
    GSH 10 mM 88.83 73.12 86.73
    GSH 15 mM 65.24 58.82 75.03
    GSH 30 mM 1.02 4.54 33.12
    DNase I 40 U 101.74 108.30 86.56
    2 part CT −0.30 0.61 21.83
    GSH 30 mM
    CIP
    10 ug/ml
    3 part CT 0.00 1.70 17.11
    GSH 30 mM
    CIP
    10 ug/ml
    DNase I
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 12: Methicillin Sensitive Staphylococcus aureus (Clinical Isolate)
  • The treatments shown in column 1 of Table 12 were tested against three strains of methicillin-sensitive Staphylococcus aureus. The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 11).
  • TABLE 12
    MSSA - 34397 MSSA - 34654 MSSA - 0800
    Treatment Left elbow Right toe DFU
    Control 100.00 100.00 100.00
    CIP 10 μg/ml 49.93 37.08 41.69
    CIP 20 μg/ml 36.78 32.05 32.03
    CIP 30 μg/ml 29.81 32.44 21.58
    GSH 10 mM 88.67 86.11 82.44
    GSH 15 mM 61.34 70.52 61.70
    GSH 30 mM 1.06 15.33 20.09
    DNase I 40 U 116.55 125.77 83.01
    2 part CT 0.77 5.85 9.68
    GSH 30 mM
    CIP10 ug/ml
    3 part CT 0.96 3.55 8.24
    GSH 30 mM
    CIP
    10 ug/ml
    DNase I
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 13: Staphylococcus agalactiae (Ex Cow Mastitis)
  • The treatments shown in column 1 of Table 13 were tested against four strains of Staphylococcus agalactiae, (veterinary strains ex Cow mastitis). The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 12).
  • TABLE 13
    S. S. S. S. S.
    agalactiae agalactiae agalactiae agalactiae agalactiae
    Treatment # 30 # 44 # 70 # 88 #106
    Control 100.00 100.00 100.00 100.00 100.00
    CIP 4 μg/ml 74.20 63.40 74.10 71.60 72.50
    CIP 8 μg/ml 66.38 66.52 65.26 69.79 70.13
    CIP 12 69.29 63.28 58.93 63.77 65.90
    μg/ml
    GSH
    10 mM 103.78 86.99 89.17 87.95 102.63
    GSH 15 mM 80.69 73.92 79.41 81.62 83.17
    GSH 30 mM 35.30 29.16 38.30 25.00 29.20
    DNase I 71.50 58.50 70.60 69.60 69.30
    40 U
    2 part CT (1) 22.30 25.90 24.80 17.80 25.30
    GSH 30 mM
    CIP 4 ug/ml
    2 part CT (2) 36.90 28.90 34.20 21.00 28.50
    GSH 30 mM
    DNase 1
    40 U
    2 part CT (3) 62.87 57.90 62.60 66.60 60.30
    CIP 30 mM
    DNase 1
    40 U
    3 part CT (1)
    GSH 10 mM 53.10 47.90 53.10 35.00 44.80
    Cip 4
    ug/ml
    DNase 1
    40 U
    3 part CT (2)
    GSH 30 mM 20.60 17.60 27.50 16.30 24.00
    CIP 10
    ug/ml
    DNase 1
    40 U
    Control = no treatment
    CIP = Ciprofloxacin
    GHS = glutathione
    • Example 14: Multi Drug Resistant Acinetobacter baumannii
  • The treatments shown in column 1 of Table 14 were tested against six clinical isolates of Multidrug resistant Acinetobacter Baumannii, (MRAB). The treatments used are given in column 1, and the % bacterial viability for each strain tested are given in the subsequent columns (see also FIG. 13). As these MRAB strains were resistant to ciprofloxacin, Amikacin was used instead.
  • TABLE 14
    MRAB 1 MRAB 2 MRAB 3 MRAB 4 MRAB 5 MRAB 12
    Strain ID 014754 014801 015069 015095 015103 016419
    Source Urine Catheter Skin Hospital Hospital Catheter
    Environ Environ
    Control 100.00 100.00 100.00 100.00 100.00 100.00
    AMI 4 μg/ml 35.91 35.99 66.60 66.36 65.23 49.66
    AMI12 μg/ml 24.47 14.11 48.60 42.91 26.85 22.70
    AMI20 μg/ml 14.67 8.36 41.70 33.92 24.60 19.80
    GSH 10 mM 73.61 70.84 84.56 68.00 65.08 80.83
    GSH 15 mM 55.58 41.23 63.18 57.70 51.49 49.05
    GSH 30 mM 20.35 2.45 37.70 13.77 16.71 18.41
    DNaseI 46.43 43.91 71.60 83.09 89.54 77.12
    2 part CT (2) 6.90 1.53 4.69 6.85 10.96 4.30
    GSH 30 mM
    AMI 4 μg/ml
    2 part CT (2) 18.61 27.60 29.50 62.75 46.11 39.81
    DNase1 40 U
    AMI 4 μg/ml
    2 part CT (3) 9.96 2.51 36.40 5.02 9.30 15.12
    GSH 30 mM
    DNase1 40 U
    3 part CT (1) 15.67 12.06 24.20 39.98 49.98 22.24
    GSH 10 mM
    AMI 4 ug/ml
    DNase1 40 U
    3 part CT (2) 3.80 0.17 0.11 4.13 5.20 2.28
    GSH 30 mM
    AMI
    10 ug/ml
    DNase1 40 U
    Control = no treatment
    AMI = Amikacin
    GHS = glutathione

Claims (29)

1-20. (canceled)
21. A biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
(a) at least one biologically acceptable thiol based antioxidant, and
(b) at least one antibiotic.
22. The composition according to claim 21 wherein the biologically acceptable thiol based antioxidant is selected from the group consisting of mercaptoethanol, N-acetyl cysteine, glutathione, thiamphenicol glycinate, acetylcysteinate, sodium mercaptoethane sulfonate, lipoic acid and erdosteine.
23. The composition according to claim 22 wherein the biologically acceptable thiol based antioxidant is glutathione.
24. The composition according to claim 21 wherein the antibiotic is selected from the group consisting of antibiotic classes Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems and mixtures thereof.
25. The composition according to claim 24 wherein the antibiotic is selected from the group consisting of ciprofloxacin, dexamethasone, amoxicillin/clavulanate, cefixime, cefaclor, clarithromycin, levofloxacin, moxifloxacin and telithromycin.
26. A biofilm disrupting composition when used for disrupting biofilms formed by non-Pseudomonad micro-organisms comprising:
(a) at least one biologically acceptable thiol based antioxidant,
(b) at least one enzyme and
(c) at least one antibiotic.
27. The composition according to claim 26 wherein the biologically acceptable thiol based antioxidant is selected from the group consisting of mercaptoethanol, N-acetyl cysteine, glutathione, thiamphenicol glycinate, acetylcysteinate, sodium mercaptoethane sulfonate, lipoic acid and erdosteine.
28. The composition according to claim 27 wherein the biologically acceptable thiol based antioxidant is glutathione.
29. The composition according to claim 26 wherein the antibiotic is selected from the group consisting of antibiotic classes Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems and mixtures thereof.
30. The composition according to claim 29 wherein the antibiotic is selected from the group consisting of ciprofloxacin, dexamethasone, amoxicillin/clavulanate, cefixime, cefaclor, clarithromycin, levofloxacin, moxifloxacin and telithromycin.
31. The composition according to claim 26 wherein the enzyme is selected from the group consisting of DNase, amylase, cellulase, and proteinase.
32. The composition according to claim 31 wherein the enzyme is DNase.
33. A process of preparing a biofilm disrupting composition according to claim 21, which process comprises combining at least one biologically acceptable thiol based antioxidant and at least one antibiotic, to form said composition.
34. A process of preparing a biofilm disrupting composition according to claim 26, which process comprises combining at least one biologically acceptable thiol based antioxidant, at least one antibiotic and at least one enzyme, to form said composition.
35. The use of a composition comprising:
(a) at least one biologically acceptable thiol based antioxidant, and
(b) at least one antibiotic,
for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms.
36. The use according to claim 35 wherein the biologically acceptable thiol based antioxidant is selected from the group consisting of mercaptoethanol, N-acetyl cysteine, glutathione, thiamphenicol glycinate, acetylcysteinate, sodium mercaptoethane sulfonate, lipoic acid and erdosteine.
37. The use according to claim 36 wherein the biologically acceptable thiol based antioxidant is glutathione.
38. The use according to claim 35 wherein the antibiotic is selected from the group consisting of antibiotic classes Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems and mixtures thereof.
39. The use according to claim 38 wherein the antibiotic is selected from the group consisting of ciprofloxacin, dexamethasone, amoxicillin/clavulanate, cefixime, cefaclor, clarithromycin, levofloxacin, moxifloxacin and telithromycin.
40. The use according to claim 39 wherein the enzyme is selected from the group consisting of DNase, amylase, cellulase, and proteinase.
41. The use of a composition comprising:
(a) at least one biologically acceptable thiol based antioxidant,
(b) at least one enzyme and
(c) at least one antibiotic,
for the manufacture of a medicament for disrupting biofilms formed by non-Pseudomonad micro-organisms.
42. The use according to claim 41 wherein the biologically acceptable thiol based antioxidant is selected from the group consisting of mercaptoethanol, N-acetyl cysteine, glutathione, thiamphenicol glycinate, acetylcysteinate, sodium mercaptoethane sulfonate, lipoic acid and erdosteine.
43. The use according to claim 42 wherein the biologically acceptable thiol based antioxidant is glutathione.
44. The use according to claim 41 wherein the antibiotic is selected from the group consisting of antibiotic classes Penicillins, Tetracyclines, Cephalosporins, Quinolones, Lincomycins, Macrolides, Sulfonamides, Glycopeptides, Aminoglycosides and Carbapenems and mixtures thereof.
45. The use according to claim 44 wherein the antibiotic is selected from the group consisting of ciprofloxacin, dexamethasone, amoxicillin/clavulanate, cefixime, cefaclor, clarithromycin, levofloxacin, moxifloxacin and telithromycin.
46. The use according to claim 45 wherein the enzyme is selected from the group consisting of DNase, amylase, cellulase, and proteinase.
47. A method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient, which method comprises administering to said patient a composition according to claim 21 in an amount which effectively disrupts said biofilm.
48. A method of disrupting biofilm formed by non-Pseudomonad micro-organisms in a patient, which method comprises administering to said patient a composition according to claim 26 in an amount which effectively disrupts said biofilm.
US16/470,887 2016-12-22 2017-12-08 Biofilm disrupting composition Abandoned US20200016231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905326A AU2016905326A0 (en) 2016-12-22 Biofilm disrupting composition
AU2016905326 2016-12-22
PCT/AU2017/051349 WO2018112511A1 (en) 2016-12-22 2017-12-08 Biofilm disrupting composition

Publications (1)

Publication Number Publication Date
US20200016231A1 true US20200016231A1 (en) 2020-01-16

Family

ID=62624084

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/470,887 Abandoned US20200016231A1 (en) 2016-12-22 2017-12-08 Biofilm disrupting composition
US16/470,904 Active 2038-12-13 US11510960B2 (en) 2016-12-22 2017-12-21 Biofilm disrupting composition for use on chronic wounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/470,904 Active 2038-12-13 US11510960B2 (en) 2016-12-22 2017-12-21 Biofilm disrupting composition for use on chronic wounds

Country Status (4)

Country Link
US (2) US20200016231A1 (en)
AU (2) AU2017381394A1 (en)
NZ (1) NZ755166A (en)
WO (3) WO2018112511A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001163UA (en) 2017-08-30 2020-03-30 Ecolab Usa Inc Molecules having one hydrophobic group and two identical hydrophilic ionic groups and compositions thereof
CN112584910B (en) 2018-08-29 2023-03-14 埃科莱布美国股份有限公司 Multi-charged ionic compounds derived from polyamines, compositions thereof and their use as reverse demulsifiers for oil and gas operations
JP7150975B2 (en) 2018-08-29 2022-10-11 エコラボ ユーエスエー インコーポレイティド Use of multiply charged cationic compounds derived from primary amines or polyamines for microbial fouling control in water systems.
CN116396183A (en) 2018-08-29 2023-07-07 埃科莱布美国股份有限公司 Ionic compounds derived from polyamines, compositions thereof and methods of making the same
US11084974B2 (en) 2018-08-29 2021-08-10 Championx Usa Inc. Use of multiple charged cationic compounds derived from polyamines for clay stabilization in oil and gas operations
US11292734B2 (en) 2018-08-29 2022-04-05 Ecolab Usa Inc. Use of multiple charged ionic compounds derived from poly amines for waste water clarification
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
CN113365498B (en) 2019-01-29 2022-10-25 埃科莱布美国股份有限公司 Use of cationic glycosyl compounds for microbial fouling control in aqueous systems
CA3128188C (en) 2019-01-29 2023-10-17 Ecolab Usa Inc. Use of cationic sugar-based compounds as corrosion inhibitors in a water system
CN118140923A (en) * 2019-02-15 2024-06-07 怀特利集团控股有限公司 Improved Endoscope Disinfectant
AU2019441168B2 (en) 2019-04-16 2023-02-02 Ecolab Usa Inc. Use of multiple charged cationic compounds derived from polyamines and compositions thereof for corrosion inhibition in a water system
CA3080524A1 (en) 2019-09-25 2021-03-25 Sani-Marc Inc. Peracetic compositions, methods and kits for removing biofilms from an enclosed surface
AU2021317744A1 (en) * 2020-07-27 2023-03-16 MUCPharm Pty Ltd Compositions and methods for treating bacterial infections
US20220031669A1 (en) * 2020-07-30 2022-02-03 Allen Gene Hirsh Compositions for Broad Spectrum Topical Antimicrobials
CN112999220B (en) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 Application of alpha-lipoic acid as and/or preparing metallo-beta-lactamase inhibitor
GB2618609A (en) 2022-05-13 2023-11-15 Lintbells Ltd Methods and processes for manufacture of a topically adherent selective bactericide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
WO2002009636A1 (en) * 2000-07-29 2002-02-07 Sonita Stummer Cap to be connected to a pouring device
DE10239321B3 (en) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosol therapy device
US8012461B2 (en) * 2004-06-08 2011-09-06 Wireley Corporation Pty Ltd Biofilm remover
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
US20110008402A1 (en) * 2006-10-13 2011-01-13 Kane Biotech Inc. Souluble b-n-acetylglucoseaminidase based antibiofilm compositions and uses thereof
JP5247459B2 (en) * 2006-10-27 2013-07-24 国立大学法人 東京大学 Amide compound and salt thereof, biofilm formation inhibitor using the same, biofilm remover and disinfectant
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2536406A4 (en) * 2010-02-03 2014-04-09 Microbion Corp Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses

Also Published As

Publication number Publication date
AU2017383101A1 (en) 2019-07-25
AU2017383101B2 (en) 2023-02-02
WO2018112544A1 (en) 2018-06-28
WO2018112511A1 (en) 2018-06-28
US11510960B2 (en) 2022-11-29
WO2018112548A1 (en) 2018-06-28
US20200085919A1 (en) 2020-03-19
NZ755166A (en) 2023-04-28
AU2017381394A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US20200016231A1 (en) Biofilm disrupting composition
AU2011373911B2 (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
Gottaslo et al. Effects of oxygen on in-vitro biofilm formation and antimicrobial resistance of Pseudomonas aeruginosae
Pompilio et al. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis
Al-Mathkhury et al. Inhibitory effect of lactobacilli filtrate on Klebsiella pneumoniae biofilm
Zafer et al. Biofilm-mediated infections by multidrug-resistant microbes: A comprehensive exploration and forward perspectives
Pani et al. Erdosteine enhances antibiotic activity against bacteria within biofilm
CN109481439A (en) Composition comprising antibacterial agent and Tazobactam Sodium
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
US8445452B2 (en) Fulvic acid and antibiotic combination
Aubert et al. In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles
Eid et al. Battling biofilm forming nosocomial pathogens using chitosan and pluronic F127
RU2672869C1 (en) Antibacterial agent based on bacteriophage
Pahomov et al. Analysis of microflora in modern outpatient clinic
Ford et al. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents
US20200215169A1 (en) Antibacterial methods and related kits
Bryant et al. Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci
Al-Kаnаany Detection Antimicrobial Suscep Tibility Рatterns of Bacterial Species Isolated from Burns and Wounds Infections in Basrah Hospitals.
Shinde et al. Antibiotic Resistance Pattern of A Biofilm Forming Bacteria, Isolated From Implanted Catheters.
Nithyamathi et al. Antimicrobial activity of Poonaga Parpam–a siddha drug
Hamad et al. Effect of β lactam antibiotics with Aminoglycosides on Multidrug Resistance Staphylococcus aureus
Thirunavukkarasu et al. Clinical evaluation of ceftriaxone and tazobactam in canine urinary tract infection
Martins et al. Chronic Superficial Infection in a Dog caused by Multidrug-Resistant Pseudomonas aeruginosa
CN110638800A (en) Application of thiobis (dichlorophenol) in resisting staphylococcus aureus biofilm infection
Sedighi et al. Antimicrobial Resistant Pattern of Pseudomonas aeruginosa Strains Isolated from Patients Referring to Hospitals of Isfahan, Iran

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION